| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel B Andersen, Jens J Hols. Peptides in the regulation of glucagon secretion. Peptides. vol 148. 2021-12-02. PMID:34748791. |
hormones that may regulate glucagon secretion include locally produced insulin and somatostatin, but also urocortin-3, amylin and pancreatic polypeptide, and from outside the pancreas glucagon-like peptide-1 and 2, peptide tyrosine tyrosine and oxyntomodulin, glucose-dependent insulinotropic polypeptide, neurotensin and ghrelin, as well as the hypothalamic hormones arginine-vasopressin and oxytocin, and calcitonin from the thyroid. |
2021-12-02 |
2023-08-13 |
Not clear |
| K V Andreassen, A T Larsen, N Sonne, K E Mohamed, M A Karsdal, K Henrikse. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats. Molecular metabolism. vol 53. 2021-11-01. PMID:34214708. |
dual amylin and calcitonin receptor agonists (dacras) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to established t2dm therapies. |
2021-11-01 |
2023-08-13 |
rat |
| Brian Baker, Barbara Schaeffler, Joe Hirman, Marcus Hompesch, Susan Pederson, Jeff Smit. Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. Endocrinology, diabetes & metabolism. vol 4. issue 2. 2021-10-18. PMID:33855218. |
in addition to its role in the pathogenesis of migraine, calcitonin gene-related peptide (cgrp) is implicated in the regulation of insulin secretion. |
2021-10-18 |
2023-08-13 |
Not clear |
| Feng Wang, Lingchi Kong, Wenbo Wang, Li Shi, Mengwei Wang, Yimin Chai, Jia Xu, Qinglin Kan. Adrenomedullin 2 improves bone regeneration in type 1 diabetic rats by restoring imbalanced macrophage polarization and impaired osteogenesis. Stem cell research & therapy. vol 12. issue 1. 2021-07-12. PMID:33985585. |
adrenomedullin 2 (adm2), an endogenous bioactive peptide belonging to the calcitonin gene-related peptide family, exhibits various biological activities associated with the inhibition of inflammation and reduction of insulin resistance. |
2021-07-12 |
2023-08-13 |
rat |
| Bernd Coester, Christelle Le Foll, Thomas A Lut. Viral depletion of calcitonin receptors in the area postrema: A proof-of-concept study. Physiology & behavior. vol 223. 2021-06-21. PMID:32497530. |
amylin is co-secreted with insulin from pancreatic ß-cells and binds to heterodimeric receptors that consist of a calcitonin core receptor (ctr) paired with receptor-activity modifying protein (ramp) 1 or 3. |
2021-06-21 |
2023-08-13 |
Not clear |
| David S Mathiesen, Asger Lund, Tina Vilsbøll, Filip K Knop, Jonatan I Bagge. Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Frontiers in endocrinology. vol 11. 2021-05-27. PMID:33488526. |
calcitonin of mammalian origin promotes insulin sensitivity, while the more potent calcitonin extracted from salmon additionally inhibits gastric emptying, promotes gallbladder relaxation, increases energy expenditure and induces satiety as well as weight loss. |
2021-05-27 |
2023-08-13 |
human |
| Charles F DeLisle, Alexander L Malooley, Indrani Banerjee, Justin L Loriea. Pro-islet amyloid polypeptide in micelles contains a helical prohormone segment. The FEBS journal. vol 287. issue 20. 2021-05-17. PMID:32077246. |
iapp is a calcitonin family peptide hormone that is cosecreted with insulin, and largely responsible for hunger satiation and metabolic homeostasis. |
2021-05-17 |
2023-08-13 |
Not clear |
| Serge Mignani, Xiangyang Shi, Andrii Karpus, Jean-Pierre Majora. Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs. European journal of medicinal chemistry. vol 209. 2021-05-03. PMID:33069435. |
this review highlighed the few examples of the association of dendrimer encapsulating drugs (e.g., small compounds: haloperidol and paeonol; macromolecular compounds: dextran, insulin and calcitonin; and sirna) using in administration. |
2021-05-03 |
2023-08-13 |
Not clear |
| Hirofumi Takeuch. [Particle Design Strategies for Developing Patient Centric Dosage Form Preparations]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 140. issue 8. 2020-09-21. PMID:32741859. |
as chitosan, a mucoadhesive polymer, was used as a coating polymer, the resultant chitosan-coated liposome was found to work as a good carrier for peptide drugs such as insulin and calcitonin in the gastrointestinal tract after oral administration. |
2020-09-21 |
2023-08-13 |
Not clear |
| Nina Sonne, Anna Thorsø Larsen, Kim Vietz Andreassen, Morten Asser Karsdal, Kim Henrikse. The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action. The Journal of pharmacology and experimental therapeutics. vol 373. issue 1. 2020-09-08. PMID:31992608. |
the dual amylin and calcitonin receptor agonist, kbp-066, induces an equally potent weight loss across a broad dose range while higher doses may further improve insulin action. |
2020-09-08 |
2023-08-13 |
rat |
| Anna Thorsø Larsen, Nina Sonne, Kim V Andreassen, Morten A Karsdal, Kim Henrikse. Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss. The Journal of pharmacology and experimental therapeutics. vol 373. issue 2. 2020-09-08. PMID:32071103. |
dual amylin and calcitonin receptor agonists (dacras) are novel candidates for treatment of type 2 diabetes and obesity because of their beneficial effects on body weight, blood glucose, insulin sensitivity, and food preference, at least short-term. |
2020-09-08 |
2023-08-13 |
rat |
| Daniel J Drucke. Advances in oral peptide therapeutics. Nature reviews. Drug discovery. vol 19. issue 4. 2020-04-09. PMID:31848464. |
it then focuses on the experience with oral peptides that have reached clinical trials, including insulin, calcitonin, parathyroid hormone and vasopressin, with an emphasis on the advances that have recently led to the landmark approval of an oral formulation of the glucagon-like peptide 1 receptor agonist semaglutide for the treatment of type 2 diabetes. |
2020-04-09 |
2023-08-13 |
Not clear |
| Stephen J Marx, David Goltzma. Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. vol 34. issue 1. 2020-04-07. PMID:30536424. |
radioimmunoassays (parathyroid hormone [pth], gastrin, insulin, prolactin, calcitonin) were breakthroughs. |
2020-04-07 |
2023-08-13 |
human |
| Beihua Zhong, Shuangtao Ma, Donna H Wan. TRPV1 Mediates Glucose-induced Insulin Secretion Through Releasing Neuropeptides. In vivo (Athens, Greece). vol 33. issue 5. 2020-01-28. PMID:31471389. |
sensory neuropeptides, including calcitonin gene-related peptide (cgrp) and substance p (sp), participate in insulin secretion. |
2020-01-28 |
2023-08-13 |
Not clear |
| Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal, Kim Henrikse. The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy. The Journal of pharmacology and experimental therapeutics. vol 370. issue 1. 2019-12-23. PMID:31028106. |
the dual amylin and calcitonin receptor agonist kbp-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy. |
2019-12-23 |
2023-08-13 |
Not clear |
| Kalyani Sridharan, Raja Kalayarasan, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Sitanshu Sekhar Kar, Lakshmana Perumal Nandhini, Rajan Palui, Harsh Durgi. Change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery. Diabetes & metabolic syndrome. vol 13. issue 3. 2019-12-13. PMID:31235148. |
change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery. |
2019-12-13 |
2023-08-13 |
Not clear |
| Kalyani Sridharan, Raja Kalayarasan, Sadishkumar Kamalanathan, Jayaprakash Sahoo, Sitanshu Sekhar Kar, Lakshmana Perumal Nandhini, Rajan Palui, Harsh Durgi. Change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery. Diabetes & metabolic syndrome. vol 13. issue 3. 2019-12-13. PMID:31235148. |
the objectives of the study were to measure the change in insulin resistance, beta cell function, glp-1 and calcitonin levels before and 2 weeks after bariatric surgery. |
2019-12-13 |
2023-08-13 |
Not clear |
| Pontirol. Peptide hormones: Review of current and emerging uses by nasal delivery. Advanced drug delivery reviews. vol 29. issue 1-2. 2019-11-20. PMID:10837581. |
luteinizing hormone releasing hormone, the analogues, desmopressin, oxytocin and salmon calcitonin are already marketed for intranasal administration; for salmon calcitonin, studies about bioavailability have been scanty in the past, but should be re-considered in order to fully explore its clinical benefit.intranasal peptide hormones not yet on the market are insulin, glucagon, growth hormone releasing hormone (ghrh) and ghrp, gh and somatostatin, but the scenario is likely to change in a short period of time. |
2019-11-20 |
2023-08-12 |
Not clear |
| Qian-Sheng Pan, Zhi-Ping Fang, Feng-Jie Huan. Identification, localization and morphology of APUD cells in gastroenteropancreatic system of stomach-containing teleosts. World journal of gastroenterology. vol 6. issue 6. 2019-11-20. PMID:11819706. |
somatostatin (som), calcitonin (cal), neurofilament (nf) and insulin (ins)-ire cells in the stomach, intestine and pancreas of 8 kinds of fish were different in distribution and types. |
2019-11-20 |
2023-08-12 |
human |
| Amrita Banerjee, Samir Mitragotr. Intestinal patch systems for oral drug delivery. Current opinion in pharmacology. vol 36. 2018-07-26. PMID:28850875. |
consequently, intestinal patch-based devices are being developed for oral delivery of several drugs such as insulin, exenatide, calcitonin, interferon-α, erythropoietin and human granulocyte colony-stimulating factor for the treatment of diabetes, osteoporosis, hepatitis or for chemotherapy. |
2018-07-26 |
2023-08-13 |
human |